NCCN
Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing
The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
NCCN Adds Prostate Cancer to Genetic Risk Assessment Guidelines
The NCCN also recently updated genetic risk guidelines for colorectal, endometrial, and gastric cancers.
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
Pre-Surgery Immunotherapy, This Time With an Anti-LAG3/PD-1 Duo, Wows Again at ESMO
After the robust activity seen in 2023 with Opdivo-Yervoy in colorectal cancer, Opdivo-relatlimab garnered attention this year with a 100 percent response rate.